Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study
This is a secondary analysis of the phase 3 ENDEAVOR study comparing relapsed and/or refractory multiple myeloma (RRMM) patients receiving carfilzomib-dexamethasone (Kd) with those receiving subcutaneous (SC) bortezomib with dexamethasone (Vd) or intravenous (IV) Vd. Of Kd-treated patients, 356 Kd w...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2018
|
| In: |
Leukemia and lymphoma
Year: 2017, Volume: 59, Issue: 6, Pages: 1364-1374 |
| ISSN: | 1029-2403 |
| DOI: | 10.1080/10428194.2017.1376743 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1080/10428194.2017.1376743 Verlag, Volltext: https://doi.org/10.1080/10428194.2017.1376743 
|
| Author Notes: | Hartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, Ruben Niesvizky, Wee-Joo Chng, Douglas Joshua, Katja Weisel, Andrew Spencer, Robert Z. Orlowski, Shibao Feng, Karim S. Iskander & Meletios A. Dimopoulos |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1581355157 | ||
| 003 | DE-627 | ||
| 005 | 20220815021829.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180927r20182017xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/10428194.2017.1376743 |2 doi | |
| 035 | |a (DE-627)1581355157 | ||
| 035 | |a (DE-576)511355157 | ||
| 035 | |a (DE-599)BSZ511355157 | ||
| 035 | |a (OCoLC)1341019406 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 245 | 1 | 0 | |a Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma |b secondary analysis of the phase 3 ENDEAVOR study |c Hartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, Ruben Niesvizky, Wee-Joo Chng, Douglas Joshua, Katja Weisel, Andrew Spencer, Robert Z. Orlowski, Shibao Feng, Karim S. Iskander & Meletios A. Dimopoulos |
| 264 | 1 | |c 2018 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published online: 22 Sep 2017 | ||
| 500 | |a Gesehen am 27.09.2018 | ||
| 520 | |a This is a secondary analysis of the phase 3 ENDEAVOR study comparing relapsed and/or refractory multiple myeloma (RRMM) patients receiving carfilzomib-dexamethasone (Kd) with those receiving subcutaneous (SC) bortezomib with dexamethasone (Vd) or intravenous (IV) Vd. Of Kd-treated patients, 356 Kd were pre-selected (by physician prior to randomization if to be randomized to Vd) for SC Vd (Kd [SC Vd]) and 108 for IV Vd (Kd [IV Vd], respectively. Of Vd-treated patients, 360 received SC Vd and 75 IV Vd. Kd (SC Vd) median PFS was not reached; SC Vd was 9.5 months. Median PFS for Kd (IV Vd) and IV Vd were 22.2 and 8.5 months, respectively. Median PFS was significantly longer and response rates were higher for Kd versus retreatment with bortezomib (SC or IV Vd) and in bortezomib naive patients. Overall, Kd was superior to Vd in RRMM regardless of route of bortezomib administration or prior bortezomib exposure. | ||
| 534 | |c 2017 | ||
| 650 | 4 | |a bortezomib | |
| 650 | 4 | |a carfilzomib | |
| 650 | 4 | |a intravenous | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a progression-free survival | |
| 650 | 4 | |a subcutaneous | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia and lymphoma |d London [u.a.] : Taylor & Francis Group, 1989 |g 59(2018), 6, Seite 1364-1374 |h Online-Ressource |w (DE-627)324746237 |w (DE-600)2030637-4 |w (DE-576)099718170 |x 1029-2403 |7 nnas |a Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma secondary analysis of the phase 3 ENDEAVOR study |
| 773 | 1 | 8 | |g volume:59 |g year:2018 |g number:6 |g pages:1364-1374 |g extent:11 |a Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma secondary analysis of the phase 3 ENDEAVOR study |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/10428194.2017.1376743 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1080/10428194.2017.1376743 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180927 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1581355157 |e 3027303961 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"role":"aut","given":"Hartmut","family":"Goldschmidt","display":"Goldschmidt, Hartmut"}],"id":{"doi":["10.1080/10428194.2017.1376743"],"eki":["1581355157"]},"relHost":[{"title":[{"title_sort":"Leukemia and lymphoma","title":"Leukemia and lymphoma"}],"pubHistory":["1.1989/90 -"],"origin":[{"publisherPlace":"London [u.a.] ; London [u.a.]","publisher":"Taylor & Francis Group ; Informa Healthcare","dateIssuedKey":"1989","dateIssuedDisp":"1989-"}],"note":["Gesehen am 08.09.15"],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma secondary analysis of the phase 3 ENDEAVOR studyLeukemia and lymphoma","physDesc":[{"extent":"Online-Ressource"}],"recId":"324746237","id":{"zdb":["2030637-4"],"issn":["1029-2403"],"eki":["324746237"]},"language":["eng"],"part":{"pages":"1364-1374","year":"2018","issue":"6","text":"59(2018), 6, Seite 1364-1374","volume":"59","extent":"11"}}],"recId":"1581355157","name":{"displayForm":["Hartmut Goldschmidt, Philippe Moreau, Heinz Ludwig, Ruben Niesvizky, Wee-Joo Chng, Douglas Joshua, Katja Weisel, Andrew Spencer, Robert Z. Orlowski, Shibao Feng, Karim S. Iskander & Meletios A. Dimopoulos"]},"physDesc":[{"extent":"11 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Published online: 22 Sep 2017","Gesehen am 27.09.2018"],"origin":[{"dateIssuedDisp":"2018","dateIssuedKey":"2018"}],"title":[{"title":"Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma","title_sort":"Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma","subtitle":"secondary analysis of the phase 3 ENDEAVOR study"}]} | ||
| SRT | |a GOLDSCHMIDCARFILZOMI2018 | ||